Inhibikase Therapeutics Inc IKT

NAS: IKT | ISIN: US45719W1062 30/04/2025

2,260 USD (+0,44%)

(+0,44%) 30/04/2025

Grafiek Inhibikase Therapeutics Inc

Grafiek Inhibikase Therapeutics Inc

1 dag1d 0,44%
1 week1w 0,00%
1 maand1m 8,13%
3 maanden3m 4,63%
6 maanden6m -14,39%
1 jaar1j 67,41%
5 jaar5j -77,17%

Inhibikase Therapeutics Inc in het nieuws

Toon enkel gratis nieuws

5 oktober 2023 · Thinking about buying stock in Gaucho Group Holdings, Inhibikase Therapeutics, Energy Transfer LP, Longeveron, or Grom Social Enterprises? · Persbericht

24 augustus 2023 · Inhibikase Therapeutics Announces Development of Novel Formulation of risvodetinib · Persbericht

22 augustus 2023 · Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders · Persbericht

21 augustus 2023 · Inhibikase Therapeutics Initiates Development of Second Generation c-Abl inhibitors and names IkT-148009 as risvodetinib · Persbericht

17 augustus 2023 · Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of IkT-001Pro · Persbericht

14 augustus 2023 · Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity · Persbericht

7 augustus 2023 · Inhibikase Therapeutics to Report Second Quarter Financial Results on August 14, 2023 · Persbericht

17 juli 2023 · Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements · Persbericht

29 juni 2023 · Inhibikase Therapeutics Announces a 1-for-6 Reverse Stock Split · Persbericht

22 juni 2023 · Inhibikase Therapeutics Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the '501' Bioequivalence Study · Persbericht

Profiel Inhibikase Therapeutics Inc

Gezondheidstechnologie

Website: www.inhibikase.com

Hoofdzetel: Atlanta, Georgia Verenigde Staten

Werknemers: 1

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe